Kramer was the CEO of Emergent BioSolutions, a government contractor hired to mass produce coronavirus vaccine doses, 400 ...

Robert G. Kramer sold nearly 90,000 shares of his stock in Emergent BioSolutions, knowing that large quantities of vaccine ...

Zhengye receives a Nasdaq notice for failing to file its 2024 annual report on time. The company has 60 days to submit a compliance plan to avoid potential delisting. Get special access to three ...

TRINITY BIOTECH ($TRIB) is expected to release its quarterly earnings data on Thursday, May 22nd before market open, per Finnhub. Analysts are expecting revenue of ...

A former biotech CEO pocketed more than $10 million by selling company stock after learning of serious COVID-19 vaccine contamination problems — before those issues were made public, according to a ...

(RTTNews) - Several small- and mid-cap stocks posted notable gains in Wednesday's after-hours trading session, even though most companies did not release fresh news. The movement was largely driven by ...

Larimar Therapeutics is deeply undervalued, trading at ~$3.40 despite a de-risked safety profile and a clear regulatory path ...

XBI biotech ETF surged 65% as M&A heats up, but 2026 brings headwinds and tougher gains. Click here for a detailed analysis.

09:35 EDT Zhengye Biotechnology (ZYBT) Holding Ltd trading halted, volatility trading pause Easily identify stocks' risks and opportunities. Discover stocks' market position with detailed competitor ...

PharmaCyte Biotech, Inc is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary ...

OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, ...

Oncolytics Biotech (NASDAQ:ONCY – Get Free Report)‘s stock had its “hold” rating reissued by research analysts at Jones Trading in a report released on Friday,Benzinga reports. Several other equities ...